The Platelet Glycoprotein 4 pipeline drugs market research report outlays comprehensive information on the Platelet Glycoprotein 4 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Platelet Glycoprotein 4 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Undisclosed, Gastrointestinal, and Immunology which include the indications Melanoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Unspecified, Inflammatory Bowel Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), and Inflammation. It also reviews key players involved in Platelet Glycoprotein 4 targeted therapeutics development with respective active and dormant or discontinued products.
The Platelet Glycoprotein 4 pipeline targets constitutes close to ten molecules. Out of which, approximately eight molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, IND/ CTA Filed, Preclinical, and Discovery stages are 1, 1, 4, and 2 respectively. Similarly, the universities portfolio in Preclinical comprises 2 molecule.
Platelet Glycoprotein 4 overview
Platelet glycoprotein 4 (CD36) is a protein that is encoded by the CD36 gene in humans. It is also known as fatty acid translocase, scavenger receptor class B member 3, glycoproteins 88, IIIb or IV. CD36 deficiency is associated with the absence (Type I) or the presence (Type II) of Glycoprotein IV on Monocytes, the phenotypic expression of the metabolic syndrome and atherosclerotic cardiovascular diseases.
For a complete picture of Platelet Glycoprotein 4’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
